News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–43
Matches
43
Sources here
4
Companies here
2
Search results Stored financial headlines

Active search

43 matching headlines

Ticker or company: GSKMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketWatch Market update Main company 🇺🇸 United States

GSK falls Monday, underperforms market

Shares of GSK PLC (GSK) fell on Monday, sliding 1.80% to £18.82, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed significantly below its 52-week high.

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

Avoiding Lag: Real-Time Signals in (GSK) Movement

This article provides real-time signal analysis for GSK, highlighting weak near-term sentiment but strong long-term projections. It offers three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels …

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

GSK (GSK) Stock Price, News & Analysis $GSK

GSK (GlaxoSmithKline plc) is a London-headquartered pharmaceutical company focused on prescription medicines, vaccines, and specialty treatments. The company's stock currently has a "Hold" consensus rating from analysts, with a price target of $53.00, approximately 5.5% higher than its current trading price. Recent news indicates …

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

GSK plc (NYSE: GSK) plans Deloitte re-appointment as external auditor from 2028

GSK plc announced its decision to re-appoint Deloitte LLP as its external auditor starting from the financial year ending December 31, 2028, following a competitive tender process. As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and …

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

GSK (NYSE: GSK) halts camlipixant cough drug after Phase III data

GSK has decided to halt further development of camlipixant for refractory chronic cough (RCC) after mixed results from its CALM-1 and CALM-2 Phase III trials. While the 50mg dose achieved the primary endpoint of reducing cough frequency in CALM-1, it failed to meet statistical …

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇦🇷 Argentina

GSK plc (NYSE: GSK) insiders add ADSs through dividend reinvestment

GSK plc reported that several senior leaders and non-executive directors acquired American Depositary Shares (ADS) between July 10 and July 14, 2026. These acquisitions were a result of the automatic reinvestment of cash dividends paid to shareholders on July 9, 2026, with ADS prices …

GSK main company GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +45.8% · Next-week setup positive 55.5% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

GSK (NYSE: GSK) closes $10.6B Nuvalent deal to expand lung cancer pipeline

GSK has completed its $10.6 billion acquisition of Nuvalent, a clinical-stage biopharmaceutical company, significantly expanding its oncology pipeline. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655), which have FDA Breakthrough Therapy and Orphan Drug Designations and are expected to …

GSK main company
Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6% GSK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context